Articles

A New Drug Application (NDA) for ganciclovir ophthalmic gel 0.15% against herpetic keratitis, submitted by Sirion Therapeutics, Inc, has been accepted for review by the FDA.

Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma

Avastin for myopic CNV

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases.

Laser reduces IOP

A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd.

Comparing DLEK with DSAEK

Posterior lamellar keratoplasty? comparison of deep lamellar endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty in the same patients: a patient's perspective

A single intravitreal injection of 4.0 mg vascular endothelial growth factor (VEGF) Trap-Eye is associated with bioactivity against diabetic macular oedema (DME), according to study results published in the January issue of the British Journal of Ophthalmology.

Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in non-neovascular age-related macular degeneration

The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

Various imaging devices fail to identify localized retinal nerve fibre layer (RNFL) defects, according to a study published in the January issue of the British Journal of Ophthalmology.

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.

The concentration of vascular endothelial growth factor (VEGF) in the vitreous is associated with the mean thickness of the fovea as measured by optical coherence tomography (OCT), according to study results published online ahead of print by Investigative Ophthalmology & Visual Science.

Performing LASIK surgery that is customized for each eye can offer more pleasing outcomes in terms of both patient safety and comfort, claims Kerry K. Assil, MD.

Professor Michael Knorz discusses his experiments on the adhesion strength of flaps, comparing the femtosecond with the microkeratome.

Azarga (brinzolamide 10 mg/ml and timolol 5 mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy.